| Ytd | -18.73% | |
| 1y | -69.08% |
| Open | 2.59 | Prev Close | 2.79 | Low | 2.53 | High | 2.75 | Mkt Cap | 14.35M |
| Vol | 664.37K | Avg Vol | 495.83K | EPS | -16.16 | P/E | N/A | Forward P/E | -0.29 |
| Beta | 1.86 | Short Ratio | 0.36 | Inst. Own | 15.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 2.58 | 200-d Avg | 5.44 | 1yr Est | 18.00 |
Moleculin Biotech Inc. (NASDAQ:MBRX) stock is trading lower on Tuesday after the company shared prel
Moleculin reports interim Phase 2/3 trial data as Annamycin shows higher remission rates than contro
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announ
Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43
Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi
Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market sessi
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announc
The poster presentation, titled "Cardiac safety of L-annamycin at high cumulative anthracycline
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the anal
Moleculin Biotech nears first MIRACLE trial data unblinding as Annamycin shows higher remission rate
Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~
The abstract titled, "Cardiac Safety of L-Annamycin Across High Cumulative Anthracycline Exposur
Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data ReleaseH
HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy an
This milestone triggers the final phase of preparation for the trial's interim 45 subject data u
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the ana
Preliminary blinded CR rate showed 67% improvement over historical cytarabine responseRoughly 35% of
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announc
– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials– Thi
As previously disclosed, on May 23, 2025, Moleculin Biotech, Inc. (the "Company") received a
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announ
HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage
Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking w
Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multifo
Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), today announ
Preclinical research to be conducted at the University of North Carolina at Chapel Hill (UNC) Annamy
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage
Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage
HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy an
Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage
Spain site opens with two R/R AML subjects enrolled; One treatedOn track to recruit 45 subjects in 4
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage
HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy an
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8)Median OS of 2nd
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.49) per share which missed the anal
Presented data highlights the potential of Annamycin for treating broad range of human cancers, incl